MedWatch

Eli Lilly scores positive phase III results with new eczema treatment

From a total of five phase III trials involving drug candidate lebrikizumab treating atopic dermatitis, three studies have produced positive results.

Photo: MIKE SEGAR/REUTERS / X90033

While Sanofil continues to triumph with eczema drug Dupixent, with Leo Pharma also working to launch its medicament, Adtralza, targeting the skin disease, both in the EU and US, Eli Lilly now moves closer to the finish line with its treatment candidate.

Eli Lilly informs that its drug candidate, lebrikizumab, rights for which were purchased from Dermira, has shown fine results in studies involving adults, children and youth aged between 12 and 18.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs